{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:14:34Z","timestamp":1787026474544,"version":"build-2736575974"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00981","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:37:05Z","timestamp":1589935025000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Facilitated Subcutaneous Immunoglobulin Replacement Therapy in Clinical Practice: A Two Center, Long-Term Retrospective Observation in Adults With Primary Immunodeficiencies"],"prefix":"10.3389","volume":"11","author":[{"given":"Ewa","family":"Wiesik-Szewczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"So\u0142dacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Paczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Jahnz-R\u00f3\u017cyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1365-2141.2009.07669.x","article-title":"Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions","volume":"145","author":"Chapel","year":"2009","journal-title":"Br J Haemat."},{"key":"B2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.iac.2018.08.001","article-title":"Personalized therapy: immunoglobulin replacement for antibody deficiency","volume":"39","author":"Wasserman","year":"2019","journal-title":"Immunol Allergy Clin North Am."},{"key":"B3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.20452\/pamw.4315","article-title":"The first Polish cohort of adult patients with common variable immunodeficiency from 4 specialized centers: do we provide standards of care?","volume":"128","author":"Wiesik-Szewczyk","year":"2018","journal-title":"Pol Arch Intern Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2147\/PPA.S60771","article-title":"Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment","volume":"8","author":"Espanol","year":"2014","journal-title":"Patient Prefer Adherence."},{"key":"B5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10875-019-0592-5","article-title":"Health-related quality of life in patients with CVID under different schedules of immunoglobulin administration: prospective multicenter study","volume":"39","author":"Pulvirenti","year":"2019","journal-title":"J Clin Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10875-016-0298-x","article-title":"Long-term tolerability, safety, and efficacy of recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulin for primary immunodeficiency","volume":"36","author":"Wasserman","year":"2016","journal-title":"J Clin Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2217\/imt-2016-0066","article-title":"Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability","volume":"8","author":"Wasserman","year":"2016","journal-title":"Immunotherapy."},{"key":"B8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1136\/jclinpath-2015-202901","article-title":"Five years of self-administered hyaluronidase facilitated subcutaneous immunoglobulin (fSCIG) home therapy in a patient with primary immunodeficiency","volume":"69","author":"Carne","year":"2016","journal-title":"J Clin Pathol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"420","DOI":"10.26226\/morressier.57bc1757d462b80290b4d094","article-title":"Facilitated subcutaneous immunoglobulin (fSCIG) in autoimmune cytopenias associated with common variable immunodeficiency","volume":"19","author":"Pedini","year":"2017","journal-title":"Isr Med Assoc J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"995","DOI":"10.2217\/imt-2016-0035","article-title":"Self-administered hyaluronidase-facilitated subcutaneous immunoglobulin therapy in complicated primary antibody deficiencies","volume":"8","author":"Danieli","year":"2016","journal-title":"Immunotherapy."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e12804","DOI":"10.1097\/MD.0000000000012804","article-title":"A case report of pregnancy in a patient with common variable immunodeficiency emphasizing the need for personalized immunoglobulin replacement","volume":"97","author":"Wiesik-Szewczyk","year":"2018","journal-title":"Medicine."},{"key":"B12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10875-016-0346-6","article-title":"Skin necrosis following subcutaneous immunoglobulin (SCIG)","volume":"37","author":"Carne","year":"2017","journal-title":"J Clin Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/cei.12694","article-title":"Facilitated subcutaneous immunoglobulin (fSCIG) therapy\u2013practical considerations","volume":"182","author":"Ponsford","year":"2015","journal-title":"Clin Exp Immunol."},{"key":"B14","unstructured":"ESID Registry - Working Definitions for Clinical Diagnosis of PID"},{"key":"B15","unstructured":""},{"key":"B16","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s11606-012-2077-6","article-title":"Shared decision making: a model for clinical practice","volume":"27","author":"Elwyn","year":"2012","journal-title":"J Gen Intern Med."},{"key":"B17","unstructured":""},{"key":"B18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jaci.2008.04.044","article-title":"Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection","volume":"122","author":"Bonagura","year":"2008","journal-title":"J Allergy Clin Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.jaci.2010.02.040","article-title":"Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years","volume":"125","author":"Lucas","year":"2010","journal-title":"J Allergy Clin Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","article-title":"Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies","volume":"137","author":"Orange","year":"2010","journal-title":"Clin Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1111\/jocn.14580","article-title":"Experiences of the burden of treatment\"-patient reports of facilitated subcutaneous immunoglobulin treatment in adults with immunodeficiency","volume":"27","author":"Petersson","year":"2018","journal-title":"J Clin Nurs."},{"key":"B22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10875-011-9511-0","article-title":"Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study","volume":"31","author":"Quinti","year":"2011","journal-title":"J Clin Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4103\/jovr.jovr_279_18","article-title":"Real life outcomes vs. clinical trial results","volume":"14","author":"Zarbin","year":"2019","journal-title":"J Ophthalmic Vis Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s10875-016-0243-z","article-title":"Quantitative evidence of wear-off effect at the end of the intravenous IgG (IVIG) dosing cycle in primary immunodeficiency","volume":"36","author":"Rojavin","year":"2016","journal-title":"J Clin Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2217\/imt.14.34","article-title":"Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies","volume":"6","author":"Wasserman","year":"2014","journal-title":"Immunotherapy."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00981\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:37:08Z","timestamp":1589935028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00981\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":25,"alternative-id":["10.3389\/fimmu.2020.00981"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00981","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,20]]},"article-number":"981"}}